{"product_id":"skin-lymphoma-the-illustrated-guide-hardback-9781394235483","title":"Skin Lymphoma; The Illustrated Guide (Hardback) 9781394235483","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eSkin Lymphoma\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eThe Illustrated Guide\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eLorenzo Cerroni (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781394235483, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 12 March 2026\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e720 pages\u003cbr\u003e27.9 x 22.4 x 3.8 cm, 2.223 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003eAn expert guide to the entire range of primary and secondary cutaneous lymphomas and pseudolymphomas\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003eIn the newly revised sixth edition of \u003ci\u003eSkin Lymphoma: The Illustrated Guide\u003c\/i\u003e, renowned dermatopathologist Dr. Lorenzo Cerroni delivers an up-to-date discussion of the entire spectrum of primary and secondary cutaneous lymphomas and pseudolymphomas of the skin. This edition includes 33 richly illustrated chapters covering primary cutaneous lymphomas, specific cutaneous manifestations of extracutaneous lymphomas and leukemias, the broad spectrum of cutaneous pseudolymphomas, and a wide variety of other clinically and pathologically relevant subjects on the topic. \u003c\/p\u003e\n\u003cp\u003eThe book offers a large collection of clinical and histopathological figures depicting everything from cutaneous NK\/T-cell and B-cell lymphomas and lymphoproliferative disorders to cutaneous atypical lymphoid proliferation. Readers will also find: \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eComprehensive explorations of cutaneous lymphomas and lymphoproliferative disorders in immune deficient and immune dysregulated patients\u003c\/li\u003e\n\u003cli\u003eDetailed coverage of composite lymphomas involving the skin\u003c\/li\u003e\n\u003cli\u003eParticular analysis of cutaneous lymphomas in pediatrics\u003c\/li\u003e\n\u003cli\u003eDedicated section on non-neoplastic cutaneous signs of hematological malignancies\u003c\/li\u003e\n\u003cli\u003eComplete overview of pseudolymphomas of the skin\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003ePerfect for dermatologists, hematologists, general pathologists, dermatopathologists, and hemato-pathologists, \u003ci\u003eSkin Lymphoma: The Illustrated Guide\u003c\/i\u003e will also benefit medical students and researchers with an interest in pathology, dermatology, and hematology.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClassification of cutaneous lymphomas 1\u003c\/p\u003e \u003cp\u003eExamination of patients 2\u003c\/p\u003e \u003cp\u003eStaging investigations 2\u003c\/p\u003e \u003cp\u003eSurgical techniques 2\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 4\u003c\/p\u003e \u003cp\u003eOther methods used in the study of cutaneous lymphoid infiltrates 11\u003c\/p\u003e \u003cp\u003eLymphoma microenvironment and lymphoma- associated microorganisms 11\u003c\/p\u003e \u003cp\u003ePseudomalignancy premalignancy and early malignancy 12\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1: Cutaneous NK\/T-cell lymphomas and lymphoproliferative disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 The “parapsoriases” 17\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Mycosis fungoides 26\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eOnset of mycosis fungoides or exacerbation of undiagnosed disease under treatment with immunomodulatory agents 28\u003c\/p\u003e \u003cp\u003eClinical features 29\u003c\/p\u003e \u003cp\u003eExtracutaneous involvement 34\u003c\/p\u003e \u003cp\u003eAssociation with other diseases 37\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 39\u003c\/p\u003e \u003cp\u003eHistopathologic differential diagnosis from inflammatory conditions 61\u003c\/p\u003e \u003cp\u003eClinical and histopathologic variants 62\u003c\/p\u003e \u003cp\u003eMycosis fungoides in children and adolescents 99\u003c\/p\u003e \u003cp\u003eTreatment 100\u003c\/p\u003e \u003cp\u003ePrognosis 111\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Sézary syndrome 135\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eOnset\/progression under systemic therapies for benign inflammatory dermatoses 137\u003c\/p\u003e \u003cp\u003eClinical features 137\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 145\u003c\/p\u003e \u003cp\u003eTreatment 149\u003c\/p\u003e \u003cp\u003ePrognosis 151\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Primary cutaneous CD30 + lymphoproliferative disorders 158\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLymphomatoid Papulosis 159\u003c\/p\u003e \u003cp\u003eCutaneous Anaplastic Large Cell Lymphoma 180\u003c\/p\u003e \u003cp\u003e“Borderline” Cases 198\u003c\/p\u003e \u003cp\u003eIntralymphatic CD30 + Large T- Cell Lymphoma 199\u003c\/p\u003e \u003cp\u003eImplant- associated anaplastic large cell lymphoma 202\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Subcutaneous panniculitis- like T- cell lymphoma 211\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 212\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 214\u003c\/p\u003e \u003cp\u003eDifferential diagnosis with other cutaneous NK\/T- cell lymphomas with prominent involvement of the subcutaneous tissue 218\u003c\/p\u003e \u003cp\u003eDifferential diagnosis with lupus panniculitis 218\u003c\/p\u003e \u003cp\u003eTreatment 219\u003c\/p\u003e \u003cp\u003ePrognosis 223\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Primary cutaneous aggressive epidermotropic CD8 + cytotoxic T- Cell lymphoma 227\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 227\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 227\u003c\/p\u003e \u003cp\u003eTreatment 233\u003c\/p\u003e \u003cp\u003ePrognosis 236\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Primary cutaneous γ\/δ T- cell lymphoma 240\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 242\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 243\u003c\/p\u003e \u003cp\u003ePrognosis 248\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Cutaneous extranodal NK\/T- cell lymphoma nasal type 254\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 254\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 256\u003c\/p\u003e \u003cp\u003eTreatment 262\u003c\/p\u003e \u003cp\u003ePrognosis 263\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Cutaneous peripheral T- cell lymphoma not otherwise specified (NOS) 266\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 267\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 268\u003c\/p\u003e \u003cp\u003eTreatment 272\u003c\/p\u003e \u003cp\u003ePrognosis 272\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Cutaneous CD4 + small– medium T- cell lymphoproliferative disorder 278\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 280\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 281\u003c\/p\u003e \u003cp\u003eTreatment 284\u003c\/p\u003e \u003cp\u003ePrognosis 284\u003c\/p\u003e \u003cp\u003eFinal considerations 284\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Primary cutaneous acral CD8 + T- cell lymphoproliferative disorder 287\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 287\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 287\u003c\/p\u003e \u003cp\u003eTreatment 288\u003c\/p\u003e \u003cp\u003ePrognosis 288\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Cutaneous adult T- cell leukemia\/lymphoma 291\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 291\u003c\/p\u003e \u003cp\u003eHistopathology 291\u003c\/p\u003e \u003cp\u003eImmunophenotype 291\u003c\/p\u003e \u003cp\u003eMolecular genetics 293\u003c\/p\u003e \u003cp\u003eTreatment 293\u003c\/p\u003e \u003cp\u003ePrognosis 293\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Specific cutaneous manifestations of nodal T- follicular helper cell lymphoma angioimmunoblastic type and of other nodal T- follicular helper cell lymphomas 296\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 296\u003c\/p\u003e \u003cp\u003eHistopathology 296\u003c\/p\u003e \u003cp\u003eImmunophenotype 299\u003c\/p\u003e \u003cp\u003eMolecular genetics 299\u003c\/p\u003e \u003cp\u003eTreatment 299\u003c\/p\u003e \u003cp\u003ePrognosis 299\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Cutaneous manifestations in Epstein– Barr virus- positive T- cell and NK- cell lymphoid proliferations and lymphomas of childhood 304\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSevere mosquito bite allergy 304\u003c\/p\u003e \u003cp\u003eHydroa- vacciniforme lymphoproliferative disorders 305\u003c\/p\u003e \u003cp\u003eClassic hydroa vacciniforme 306\u003c\/p\u003e \u003cp\u003eSystemic hydroa vacciniforme lymphoproliferative disorder 309\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2: Cutaneous B-cell lymphomas and lymphoproliferative disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Cutaneous follicle center lymphoma 317\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 317\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 321\u003c\/p\u003e \u003cp\u003eDifferential diagnosis of cutaneous follicle center lymphoma diffuse type from cutaneous diffuse large B- cell lymphoma leg type 336\u003c\/p\u003e \u003cp\u003eTreatment 336\u003c\/p\u003e \u003cp\u003ePrognosis 337\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Primary cutaneous marginal zone lymphoproliferative disorder (primary cutaneous marginal zone lymphoma) and variants 341\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCutaneous marginal zone lymphoproliferative disorder conventional variant 343\u003c\/p\u003e \u003cp\u003eClinical features 344\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 345\u003c\/p\u003e \u003cp\u003eTreatment 354\u003c\/p\u003e \u003cp\u003ePrognosis 355\u003c\/p\u003e \u003cp\u003eCutaneous marginal zone lymphoproliferative disorder lymphoplasmacytic variant 356\u003c\/p\u003e \u003cp\u003eClinical features 356\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 356\u003c\/p\u003e \u003cp\u003eTreatment 358\u003c\/p\u003e \u003cp\u003ePrognosis 358\u003c\/p\u003e \u003cp\u003eCutaneous marginal zone lymphoproliferative disorder plasmacytic variant 359\u003c\/p\u003e \u003cp\u003eClinical features 359\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 359\u003c\/p\u003e \u003cp\u003eTreatment and prognosis 359\u003c\/p\u003e \u003cp\u003eCutaneous marginal zone lymphoproliferative disorder blastoid variant 361\u003c\/p\u003e \u003cp\u003eClinical features 361\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 361\u003c\/p\u003e \u003cp\u003eTreatment and prognosis 362\u003c\/p\u003e \u003cp\u003eCutaneous amyloidoma 362\u003c\/p\u003e \u003cp\u003eClinical features 364\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 364\u003c\/p\u003e \u003cp\u003eTreatment and prognosis 364\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Cutaneous diffuse large B- cell lymphoma leg type 370\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 371\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 372\u003c\/p\u003e \u003cp\u003eTreatment 380\u003c\/p\u003e \u003cp\u003ePrognosis 380\u003c\/p\u003e \u003cp\u003ePrimary cutaneous diffuse large B- cell lymphoma Nos 381\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Intravascular large cell lymphomas 387\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntravascular large B- cell lymphoma 388\u003c\/p\u003e \u003cp\u003eIntravascular large NK\/T- cell lymphoma 394\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Other cutaneous B- cell lymphomas 400\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCutaneous manifestations of Epstein– Barr virus (EBV)- positive diffuse large B- cell lymphoma 400\u003c\/p\u003e \u003cp\u003eCutaneous manifestations of mantle cell lymphoma 403\u003c\/p\u003e \u003cp\u003eCutaneous manifestations of extracavitary primary effusion lymphoma 408\u003c\/p\u003e \u003cp\u003eCutaneous manifestations of multiple myeloma 411\u003c\/p\u003e \u003cp\u003eCutaneous manifestations of Burkitt lymphoma 414\u003c\/p\u003e \u003cp\u003eCutaneous lymphomatoid granulomatosis 416\u003c\/p\u003e \u003cp\u003eCutaneous plasmablastic lymphoma 419\u003c\/p\u003e \u003cp\u003eCutaneous T- cell\/histiocyte- rich large B- cell lymphoma 420\u003c\/p\u003e \u003cp\u003eCutaneous manifestations of Waldenström macroglobulinemia 424\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3: Cutaneous lymphomas and lymphoproliferative disorders in the setting of immune deficiency \/ dysregulation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Cutaneous lymphoproliferative disorders and lymphomas in the setting of immune deficiency\/ dysregulation 433\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePosttransplant immunodeficiency\/dysregulation 439\u003c\/p\u003e \u003cp\u003eHuman immunodeficiency virus (HIV)- related immune deficiency\/dysregulation 439\u003c\/p\u003e \u003cp\u003eCutaneous plasmacytic hyperplasia associated with immune deficiency\/dysregulation 441\u003c\/p\u003e \u003cp\u003eCutaneous polymorphic B- cell lymphoproliferative disorder associated with immune deficiency\/ dysregulation 443\u003c\/p\u003e \u003cp\u003eEpstein– Barr virus (EBV)- associated mucocutaneous ulcers 446\u003c\/p\u003e \u003cp\u003eCutaneous manifestations of multicentric Castleman disease 448\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 4: Specific cutaneous manifestations of leukemias and of precursor hematologic neoplasms\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Cutaneous manifestations of B- cell chronic lymphocytic leukemia 455\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 455\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 456\u003c\/p\u003e \u003cp\u003eTreatment and prognosis 461\u003c\/p\u003e \u003cp\u003eProgression to diffuse large B- cell lymphoma (Richter syndrome) 464\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Cutaneous manifestations of myelogenous leukemia 471\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAcute myeloid leukemia 472\u003c\/p\u003e \u003cp\u003eChronic myelogenous leukemia 484\u003c\/p\u003e \u003cp\u003eMyelodysplastic syndromes (myelodysplastic neoplasms) 489\u003c\/p\u003e \u003cp\u003eMature plasmacytoid dendritic cell proliferation associated with myeloid neoplasms 492\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Blastic plasmacytoid dendritic cell neoplasm 495\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 495\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 497\u003c\/p\u003e \u003cp\u003eTreatment 502\u003c\/p\u003e \u003cp\u003ePrognosis 503\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Cutaneous manifestations of other leukemias 507\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eT- cell prolymphocytic leukemia 507\u003c\/p\u003e \u003cp\u003eAggressive natural killer cell leukemia 509\u003c\/p\u003e \u003cp\u003eSpecific skin manifestations of other types of leukemia 510\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26 Cutaneous lymphoblastic lymphomas 513\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCutaneous B- Lymphoblastic Lymphoma 513\u003c\/p\u003e \u003cp\u003eClinical features 514\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 514\u003c\/p\u003e \u003cp\u003eDifferential diagnosis 516\u003c\/p\u003e \u003cp\u003eTreatment and prognosis 517\u003c\/p\u003e \u003cp\u003eCutaneous T- Lymphoblastic Lymphoma 518\u003c\/p\u003e \u003cp\u003eClinical features 518\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 519\u003c\/p\u003e \u003cp\u003eTreatment and prognosis 519\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 5: Cutaneous manifestations of other lymphomas and non-neoplastic cutaneous signs of systemic lymphomas\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27 Cutaneous manifestations of Hodgkin lymphoma 527\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 528\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 528\u003c\/p\u003e \u003cp\u003eTreatment and prognosis 530\u003c\/p\u003e \u003cp\u003ePrimary cutaneous Hodgkin lymphoma 530\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28 Cutaneous composite lymphomas 533\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 534\u003c\/p\u003e \u003cp\u003eHistopathology immunophenotype and molecular genetics 534\u003c\/p\u003e \u003cp\u003eTreatment and prognosis 538\u003c\/p\u003e \u003cp\u003e\u003cb\u003e29 Non- neoplastic cutaneous signs of systemic lymphomas 541\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 6: Cutaneous lymphomas and lymphoproliferative disorders in children and adolescents\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e30 Cutaneous lymphomas and lymphoproliferative disorders in children and adolescents 599\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMycosis fungoides 599\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 7: Pseudolymphomas of the skin\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e31 Pseudolymphomas of the skin 577\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChronic actinic dermatitis (actinic reticuloid) 578\u003c\/p\u003e \u003cp\u003eLymphomatoid contact dermatitis 580\u003c\/p\u003e \u003cp\u003ePseudolymphomatous atopic dermatitis and other eczematous dermatoses 582\u003c\/p\u003e \u003cp\u003eNon- neoplastic erythroderma in adult patients 592\u003c\/p\u003e \u003cp\u003eSolitary idiopathic T\/B- cell pseudolymphoma 598\u003c\/p\u003e \u003cp\u003eLichenoid\/lymphomatoid keratosis 600\u003c\/p\u003e \u003cp\u003ePityriasis lichenoides 601\u003c\/p\u003e \u003cp\u003eLichen aureus\/lichenoid pigmented purpuric dermatitis 605\u003c\/p\u003e \u003cp\u003eLichen sclerosus 606\u003c\/p\u003e \u003cp\u003eVitiligo (inflammatory stage) 609\u003c\/p\u003e \u003cp\u003eAnnular lichenoid dermatitis of youth 609\u003c\/p\u003e \u003cp\u003ePseudolymphomatous cutaneous infiltrates in human immunodeficiency virus (HIV)- infected patients and in other immune deficiencies 609\u003c\/p\u003e \u003cp\u003eCD30 + T- cell pseudolymphomas 614\u003c\/p\u003e \u003cp\u003ePersistent nodular arthropod bite reactions and nodular scabies 616\u003c\/p\u003e \u003cp\u003ePseudolymphomas in herpes simplex and herpes zoster infections 620\u003c\/p\u003e \u003cp\u003ePseudolymphomas associated with lupus erythematosus 621\u003c\/p\u003e \u003cp\u003eLymphomatoid drug reactions 630\u003c\/p\u003e \u003cp\u003eLymphocytoma cutis 633\u003c\/p\u003e \u003cp\u003ePseudolymphomas associated with infections by Borrelia species 635\u003c\/p\u003e \u003cp\u003ePseudolymphomas at sites of vaccination 642\u003c\/p\u003e \u003cp\u003eLocalized scleroderma\/morphea 647\u003c\/p\u003e \u003cp\u003eCutaneous IgG4- related disease 649\u003c\/p\u003e \u003cp\u003ePseudolymphomas in syphilis 649\u003c\/p\u003e \u003cp\u003eCutaneous plasma cell granuloma 654\u003c\/p\u003e \u003cp\u003eCutaneous and systemic plasmacytosis 655\u003c\/p\u003e \u003cp\u003eAngiomatoid pseudolymphoma (T- cell- rich angiomatoid polypoid pseudolymphoma \/ Acral pseudolymphomatous angiokeratoma in children \/ Pre- tibial lymphoplasmacytic plaque in children) 655\u003c\/p\u003e \u003cp\u003eCutaneous extramedullary hematopoiesis 658\u003c\/p\u003e \u003cp\u003eHistiocytoid cells in Sweet syndrome and other conditions 659\u003c\/p\u003e \u003cp\u003eIntralymphatic histiocytosis 661\u003c\/p\u003e \u003cp\u003eBenign intralymphatic proliferation of T- cell lymphoid blasts 662\u003c\/p\u003e \u003cp\u003eOther “accidental” pseudolymphomas 667\u003c\/p\u003e \u003cp\u003e\u003cb\u003e32 Nonlymphoid malignant neoplasms of the skin mimicking histopathologically cutaneous lymphomas (“malignant pseudolymphomas”) 677\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 8: The cutaneous “atypical lymphoid proliferation”\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e33 The cutaneous “atypical lymphoid proliferation” 687\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIndex 690\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Other branches of medicine [\u003ca title=\"See our other books on Other branches of medicine\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Other%20branches%20of%20medicine%20%5BMM%5D%22\"\u003eMM\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52405465383192,"sku":"9781394235483","price":129.28,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781394235483.jpg?v=1784135008","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/skin-lymphoma-the-illustrated-guide-hardback-9781394235483","provider":"Freshly Printed Books","version":"1.0","type":"link"}